136 related articles for article (PubMed ID: 37260320)
21. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
Mishra A; Pal L; Mishra SK
World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
[TBL] [Abstract][Full Text] [Related]
22. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
23. Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma.
Wei S; Gao M; Zhao C; Pan Y; Li H; Li J; Li X
Int J Clin Oncol; 2014 Oct; 19(5):800-4. PubMed ID: 24096868
[TBL] [Abstract][Full Text] [Related]
24. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
Carvalho DP; Ferreira AC
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
[TBL] [Abstract][Full Text] [Related]
25. Radioiodine therapy of thyroid carcinoma following Pax-8 gene transfer.
Mu D; Huang R; Ma X; Li S; Kuang A
Gene Ther; 2012 Apr; 19(4):435-42. PubMed ID: 21833035
[TBL] [Abstract][Full Text] [Related]
26. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
27. Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas.
Lee SJ; Choi KC; Han JP; Park YE; Choi MG
J Endocrinol Invest; 2007 Jan; 30(1):28-34. PubMed ID: 17318019
[TBL] [Abstract][Full Text] [Related]
28. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.
Dong H; Shen WZ; Yan YJ; Yi JL; Zhang L
J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):77-81. PubMed ID: 26838744
[TBL] [Abstract][Full Text] [Related]
29. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.
Knauf JA; Kuroda H; Basu S; Fagin JA
Oncogene; 2003 Jul; 22(28):4406-12. PubMed ID: 12853977
[TBL] [Abstract][Full Text] [Related]
30. Redox Homeostasis in Thyroid Cancer: Implications in Na
Cazarin J; Dupuy C; Pires de Carvalho D
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682803
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.
Cai X; Wang R; Tan J; Meng Z; Li N
Clin Transl Oncol; 2021 Dec; 23(12):2403-2414. PubMed ID: 34100218
[TBL] [Abstract][Full Text] [Related]
32. Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents.
Patel A; Jhiang S; Dogra S; Terrell R; Powers PA; Fenton C; Dinauer CA; Tuttle RM; Francis GL
Pediatr Res; 2002 Nov; 52(5):737-44. PubMed ID: 12409522
[TBL] [Abstract][Full Text] [Related]
33. MiR-181a-5p Regulates NIS Expression in Papillary Thyroid Carcinoma.
Gierlikowski W; Broniarek K; Cheda Ł; Rogulski Z; Kotlarek-Łysakowska M
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199867
[TBL] [Abstract][Full Text] [Related]
34. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
[TBL] [Abstract][Full Text] [Related]
35. Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells.
Zhang H; Chen D
Thyroid Res; 2018; 11():13. PubMed ID: 30337961
[TBL] [Abstract][Full Text] [Related]
36. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
37. Analysis of human sodium/iodide symporter, thyroid transcription factor-1, and paired-box-protein-8 gene expression in benign thyroid diseases.
Joba W; Spitzweg C; Schriever K; Heufelder AE
Thyroid; 1999 May; 9(5):455-66. PubMed ID: 10365677
[TBL] [Abstract][Full Text] [Related]
38. HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells.
Chai W; Ye F; Zeng L; Li Y; Yang L
J Exp Clin Cancer Res; 2019 Jul; 38(1):325. PubMed ID: 31331356
[TBL] [Abstract][Full Text] [Related]
39. MEK signaling modulates sodium iodide symporter at multiple levels and in a paradoxical manner.
Vadysirisack DD; Venkateswaran A; Zhang Z; Jhiang SM
Endocr Relat Cancer; 2007 Jun; 14(2):421-32. PubMed ID: 17639055
[TBL] [Abstract][Full Text] [Related]
40. Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells.
Chen JY; Wang JJ; Lee HC; Chi CW; Lee CH; Hsu YC
J Chin Med Assoc; 2020 Oct; 83(10):923-930. PubMed ID: 33009242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
